These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Fujiwara M; Yagi H; Matsuoka R; Akimoto K; Furutani M; Imamura S; Uehara R; Nakayama T; Takao A; Nakazawa M; Saji T Circ J; 2008 Jan; 72(1):127-33. PubMed ID: 18159113 [TBL] [Abstract][Full Text] [Related]
9. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711 [TBL] [Abstract][Full Text] [Related]
10. Too late, again? Jones NL Can Respir J; 2001; 8(3):127-8. PubMed ID: 11420587 [No Abstract] [Full Text] [Related]
11. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Archer SL; Djaballah K; Humbert M; Weir KE; Fartoukh M; Dall'ava-Santucci J; Mercier JC; Simonneau G; Dinh-Xuan AT Am J Respir Crit Care Med; 1998 Oct; 158(4):1061-7. PubMed ID: 9769261 [TBL] [Abstract][Full Text] [Related]
12. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Machado RD; James V; Southwood M; Harrison RE; Atkinson C; Stewart S; Morrell NW; Trembath RC; Aldred MA Circulation; 2005 Feb; 111(5):607-13. PubMed ID: 15699281 [TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Sztrymf B; Coulet F; Girerd B; Yaici A; Jais X; Sitbon O; Montani D; Souza R; Simonneau G; Soubrier F; Humbert M Am J Respir Crit Care Med; 2008 Jun; 177(12):1377-83. PubMed ID: 18356561 [TBL] [Abstract][Full Text] [Related]
15. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496 [TBL] [Abstract][Full Text] [Related]
16. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine. Davis WM; Waters IW Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375 [TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. Kabata H; Satoh T; Kataoka M; Tamura Y; Ono T; Yamamoto M; Huqun ; Hagiwara K; Fukuda K; Betsuyaku T; Asano K Respirology; 2013 Oct; 18(7):1076-82. PubMed ID: 23675998 [TBL] [Abstract][Full Text] [Related]
18. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. Morse J; Barst R; Horn E; Cuervo N; Deng Z; Knowles J J Rheumatol; 2002 Nov; 29(11):2379-81. PubMed ID: 12415595 [TBL] [Abstract][Full Text] [Related]
19. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Walker AM; Langleben D; Korelitz JJ; Rich S; Rubin LJ; Strom BL; Gonin R; Keast S; Badesch D; Barst RJ; Bourge RC; Channick R; Frost A; Gaine S; McGoon M; McLaughlin V; Murali S; Oudiz RJ; Robbins IM; Tapson V; Abenhaim L; Constantine G Am Heart J; 2006 Sep; 152(3):521-6. PubMed ID: 16923424 [TBL] [Abstract][Full Text] [Related]
20. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Atkinson C; Stewart S; Upton PD; Machado R; Thomson JR; Trembath RC; Morrell NW Circulation; 2002 Apr; 105(14):1672-8. PubMed ID: 11940546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]